A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting

This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.

开始日期2026-04-01

申办/合作机构

Kumquat Biosciences, Inc.

NCT06645886

/ Recruiting临床1期

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hematologic Malignancies

The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are:
* What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs?
* Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor?
* What happens to KQB198 in the body?
Participants will:
* Take KQB198 daily, alone or in combination with another anti-cancer drug
* Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

开始日期2024-12-09

申办/合作机构

Kumquat Biosciences, Inc.

NCT06507306

/ Recruiting临床1期

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB198 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are:
* What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs?
* Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor?
* What happens to KQB198 in the body?
Participants will:
* Take KQB198 daily, alone or in combination with another anti-cancer drug
* Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

开始日期2024-06-03

申办/合作机构

Kumquat Biosciences, Inc.

100 项与 KQB-198 相关的临床结果

登录后查看更多信息

100 项与 KQB-198 相关的转化医学

登录后查看更多信息

100 项与 KQB-198 相关的专利（医药）

登录后查看更多信息

100 项与 KQB-198 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性胃肠道间质瘤	临床2期	-	Kumquat Biosciences, Inc.	2026-04-01
转移性肿瘤	临床2期	-	Kumquat Biosciences, Inc.	2026-04-01
血液肿瘤	临床1期	澳大利亚	Kumquat Biosciences, Inc.	2025-01-30
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	美国	Kumquat Biosciences, Inc.	2024-12-09
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	法国	Kumquat Biosciences, Inc.	2024-12-09
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	德国	Kumquat Biosciences, Inc.	2024-12-09
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	意大利	Kumquat Biosciences, Inc.	2024-12-09
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	荷兰	Kumquat Biosciences, Inc.	2024-12-09
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	波兰	Kumquat Biosciences, Inc.	2024-12-09
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	西班牙	Kumquat Biosciences, Inc.	2024-12-09